Search Results - "Kish, J A"

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study by Forastiere, A A, Metch, B, Schuller, D E, Ensley, J F, Hutchins, L F, Triozzi, P, Kish, J A, McClure, S, VonFeldt, E, Williamson, S K

“…The Southwest Oncology Group (SWOG) conducted a randomized comparison of cisplatin plus fluorouracil (5-FU) and carboplatin plus 5-FU versus single-agent…”
Get more information

A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis by Hesketh, P J, Harvey, W H, Harker, W G, Beck, T M, Ryan, T, Bricker, L J, Kish, J A, Murphy, W K, Hainsworth, J D, Haley, B

“…This study compares the efficacy and safety of ondansetron alone with that of ondansetron plus dexamethasone in the prevention of emesis induced by high-dose…”
Get more information

Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting by Beck, T M, Hesketh, P J, Madajewicz, S, Navari, R M, Pendergrass, K, Lester, E P, Kish, J A, Murphy, W K, Hainsworth, J D, Gandara, D R

“…This study compares the efficacy and safety of two single-dose regimens with the approved three-dose regimen of ondansetron in the prevention of…”
Get more information

Metastatic squamous cell carcinoma of an unknown primary localized to the neck. Advantages of an aggressive treatment by de Braud, F, Heilbrun, L K, Ahmed, K, Sakr, W, Ensley, J F, Kish, J A, Tapazoglou, E, al-Sarraf, M

“…Treatment of patients with squamous cell carcinoma (SCC) of an unknown primary localized to the neck is still controversial, particularly regarding advanced…”
Get more information

Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study by Kish, J A, Wolf, M, Crawford, E D, Leimert, J T, Bueschen, A, Neefe, J R, Flanigan, R C

“…The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5.6%. Low dose continuous 5-fluorouracil (5-FU) has…”
Get more information

The incidence and significance of thromboembolic complications in patients with high-grade gliomas by Cheruku, R, Tapazoglou, E, Ensley, J, Kish, J A, Cummings, G D, al-Sarraf, M

“…Coagulation system abnormalities in patients with malignancy ranges from asymptomatic laboratory abnormalities to overt clinical manifestations. To determine…”
Get more information

Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck by Kish, J A, Weaver, A, Jacobs, J, Cummings, G, Al-Sarraf, M

“…The combination of cisplatin and 96-hour infusion of 5-fluorouracil (5-FU) was evaluated in 30 patients with recurrent (local and regional) and disseminated…”
Get more information

Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck by Ensley, J F, Jacobs, J R, Weaver, A, Kinzie, J, Crissman, J, Kish, J A, Cummings, G, Al-Sarraf, M

“…Induction chemotherapy, followed by surgery and/or radiotherapy was utilized in patients with advanced squamous cell carcinoma of the head and neck. During…”
Get more information

A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck by Kish, J A, Ensley, J F, Jacobs, J, Weaver, A, Cummings, G, Al-Sarraf, M

“…One of the most active chemotherapeutic regimens for treatment of advanced and recurrent head and neck cancer is cisplatin (CACP) + 5-fluorouracil (5-FU)…”
Get more information

Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer by Kish, J A, Ensley, J F, Jacobs, J R, Binns, P, al-Sarraf, M

“…The combination of cisplatin and 5-fluorouracil (5-FU) infusion in head and neck cancer patients produces an overall response rate of 90% for advanced disease…”
Get more information

Outcomes of Phase I Trial of Patients With Recurrent Head and Neck Squamous Cell Carcinoma Treated With Re-Irradiation With Stereotactic Body Radiation Therapy and Concurrent Cisplatin by Echevarria, M., Chung, C., Kirtane, K., Kish, J.A., Muzaffar, J., Caudell, J.J.

“…Stereotactic body radiation therapy (SBRT) offers a treatment option for patients with unresectable, previously radiated, locoregionally recurrent head and…”
Get full text

Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy by DiBenedetto, Joseph, Cubeddu, Luigi X., Ryan, Thomas, Kish, Julie A., Sciortino, David, Beall, Charles, Eisenberg, Peter D., Henderson, Charles, Griffin, Dan, Wentz, Alison

“…This multicenter, randomized, double-blind study compared the efficacy and tolerability of ondansetron 8 mg twice daily for 3 days with placebo in preventing…”
Get full text

The Wayne State University experience with adjuvant chemotherapy of head and neck cancer by al-Sarraf, M, Kish, J A, Ensley, J F

“…Because of the poor results of standard therapy in patients with locally advanced head and neck cancers, chemotherapy is increasingly used to improve the…”
Get more information

Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder : A Southwest Oncology Group trial by KISH, J. A, WOLF, M. K, SCHELLHAMMER, P. F, HUSSAIN, M. H. A, EINSTEIN, A. B, CRAWFORD, E. D

“…Significant toxicities result from the use of MVAC (methotrexate, vinblastine, adriamycin, cisplatin) for advanced/ recurrent transitional cell carcinoma of…”
Get full text

Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer by Weaver, A, Fleming, S, Ensley, J, Kish, J A, Jacobs, J, Kinzie, J, Crissman, J, Al-Sarraf, M

“…One hundred ninety-one patients were treated by one of three cisplatin-containing multidrug protocols. The initial 77 patients received two courses of…”
Get more information

The clinical syndrome of 5-fluorouracil cardiotoxicity by ENSLEY, J. F, BHARAT PATEL, KLONER, R, KISH, J. A, WYNNE, J, MUHYI AL-SARRAF

“…5-fluorouracil (FUra) is one of the most frequently used drugs in cancer treatment, particularly in combination with other agents. Its activity when…”
Get full text

The correlation of specific variables of tumor differentiation with response rate and survival in patients with advanced head and neck cancer treated with induction chemotherapy by Ensley, J F, Kish, J A, Weaver, A A, Jacobs, J R, Hassan, M, Cummings, G, Al-Sarraf, M

“…The authors have reported previously that conventionally defined grades of tumor morphology do not correlate with tumor response or survival in advanced…”
Get more information

Aclacinomycin. Phase II evaluation in advanced squamous carcinoma of the head and neck by Kish, J A, Al-Sarraf, M

“…Aclacinomycin-A was evaluated in a phase II trial for advanced head and neck cancer. A weekly infusion of 65 mg/m2 was used. Eighteen patients were entered…”
Get more information

Phase II evaluation of amonafide in renal cell carcinoma : a southwest oncology group study by HIGANO, C. S, GOODMAN, P, CRAIG, J. B, KISH, J. A, RIVKIN, S. E, WOLF, M, CRAWFORD, E. D

“…Twenty four patients with advanced renal cell carcinoma were treated in a phase II trial with amonafide 300-450 mg/m2/day on days 1-5 every 21 days. There were…”
Get full text

Phase II evaluation of 4'deoxydoxorubicin in advanced renal cell carcinoma by Kish, J A, Ensley, J F, al-Sarraf, M

“…4'Deoxydoxorubicin was evaluated in patients with advanced renal carcinoma. Only one partial remission was noted, and no significant cardiac toxicity was seen…”
Get more information